Denali Therapeutics Inc.
About Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$512.5M
- Total assets
- $1.1B
- Market cap
- $3.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $555.3M
- Operating income
- -$555.3M
- Income tax
- $102.0K
- Net income
- -$512.5M
- EPS (basic)
- $-2.97
- EPS (diluted)
- $-2.97
Balance sheet
- Total assets
- $1.1B
- Current assets
- $900.7M
- Total liabilities
- $131.1M
- Current liabilities
- $98.4M
- Shareholders’ equity
- $1.0B
Cash flow
- Operating cash flow
- -$412.6M
- Investing cash flow
- $255.3M
- Financing cash flow
- $189.2M
- Net cash flow
- $31.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.1B
- EPS (diluted)
- $-2.97
- Shares outstanding
- 158.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 8, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $512.5M in FY2025.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Denali Therapeutics Inc..
Write a review
News about Denali Therapeutics Inc.
News & sentiment via Polygon.io
